I-MAB (IMAB) Other Long-Term Liabilities : $13.74 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Other Long-Term Liabilities?

I-MAB's other long-term liabilities for the quarter that ended in Dec. 2023 was $13.74 Mil.

I-MAB's quarterly other long-term liabilities increased from Dec. 2022 ($12.72 Mil) to Jun. 2023 ($15.89 Mil) but then declined from Jun. 2023 ($15.89 Mil) to Dec. 2023 ($13.74 Mil).

I-MAB's annual other long-term liabilities declined from Dec. 2021 ($15.22 Mil) to Dec. 2022 ($12.72 Mil) but then increased from Dec. 2022 ($12.72 Mil) to Dec. 2023 ($13.74 Mil).

I-MAB Other Long-Term Liabilities Historical Data

The historical data trend for I-MAB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Other Long-Term Liabilities Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial								-	-	-	-	-

I-MAB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

I-MAB Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of I-MAB's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.